arXiv:2608. 05196v1 Announce Type: new Abstract: Multiple sclerosis (MS) is diagnosed through clinical assessment, magnetic resonance imaging, laboratory evidence when appropriate, and exclusion of better explanations.
arXiv:2607. 16250v1 Announce Type: cross Abstract: Estrogen Receptor (ER) status is a critical biomarker in breast cancer diagnosis, prognosis, and treatment selection.
arXiv:2607. 04486v1 Announce Type: new Abstract: Diagnosing and monitoring diseases frequently involves the analysis of human biological samples, with blood analysis being pivotal.
An interpretable multi‑instance learning classifier based on a decision tree was developed to predict NPM1 and FLT3‑ITD mutations in acute myeloid leukemia using routine flow cytometry data. In cross‑validation on 197 patients, the model achieved AUROCs of 0.96 for NPM1 and 0.86 for FLT3‑ITD, outperforming a clinical baseline and matching deep learning methods. On an independent cohort of 161 patients, it maintained high performance with AUROCs of 0.90 and 0.82, and positive predictive values of 0.87 and 0.68, while cell‑level interpretation recovered known immunophenotypic signatures.
The study benchmarks active spot selection methods against random sampling for spatial transcriptomics, focusing on cost‑efficient data acquisition. Using two public cohorts, the authors simulate multi‑round selection with uncertainty‑based (MC‑dropout, TOD) and diversity‑based (CoreSet, TypiClust) strategies, evaluating performance at 5%, 10%, 30%, and 50% of the spot pool. Results show that none of the active strategies consistently outperforms random sampling across all budgets or evaluation metrics, with performance varying by dataset and metric.
arXiv:2512. 22240v5 Announce Type: replace-cross Abstract: Machine learning models are primarily judged by predictive performance, especially in applied genomics, where explanations are read as biological findings.
arXiv:2606. 16337v1 Announce Type: new Abstract: Predictive modeling for clinical tabular data is central to clinical decision support and therefore requires not only strong predictive performance but also transparent decision logic.
arXiv:2607. 03466v1 Announce Type: cross Abstract: This study aims to predict Tumor, Node, and Metastasis (TNM) stage labels independently, with the Cancer Genome Atlas (TCGA) pathology report as the sixth shared task of SMM4H-HeaRD 2026.
arXiv:2608. 12805v1 Announce Type: new Abstract: Access to clinical data is essential for developing reliable healthcare machine learning systems, but direct use of electronic health records is constrained by privacy regulation, institutional review, data-use agreements, and the risk of re-identification.
Frozen hematology foundation-model (FM) embeddings reach near-saturated in-domain white-blood-cell (WBC) accuracy, but clinical deployment demands reliability across scanners, sites, stains and prepar...
The study evaluates 15 frozen hematology foundation-model embeddings across four single‑cell acquisition domains, finding that while in‑domain accuracy is near‑saturated (macro‑F1 0.98–0.997), cross‑dataset performance drops dramatically (34–72%) and model rankings shift. Probe‑dependent rank transfer is observed, with 1‑NN retrieval more stable than linear heads, yet neither reliably predicts target robustness. Calibration deteriorates off‑domain (ECE rises from 0.004 to 0.35), and exposure to internal cohorts confounds shift analysis; a training‑free pseudo‑label‑balanced feature normalization (CBR) modestly improves target‑prior robustness and calibration. whyItMatters":"The findings highlight that frozen hematology foundation models, though accurate in‑domain, may fail under realistic scanner, site, and class‑prior shifts, underscoring the need for comprehensive audits of accuracy, calibration, exposure, and robustness before clinical deployment."
arXiv:2609.22734v1 Announce Type: cross Abstract: Clinical domain classification plays an important role in organizing and analyzing large volumes of unstructured medical text. However, medical trans...
arXiv:2606. 11144v1 Announce Type: new Abstract: Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark exists for training or evaluating computational models on the corresponding longitudinal patient trajectories.